From mutational inactivation to aberrant gain‐of‐function: Unraveling the structural basis of mutant p53 oncogenic transition

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-4644|119|3|2646-2652

ISSN： 0730-2312

Source： JOURNAL OF CELLULAR BIOCHEMISTRY, Vol.119, Iss.3, 2018-03, pp. : 2646-2652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers

By Ferraiuolo Maria   Verduci Lorena   Blandino Giovanni   Strano Sabrina  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-05 ,pp. : 961-961

MDPI

Access to resources Recommend Favorite

Suppression of the STK15 oncogenic activity requires a transactivation‐independent p53 function

By  

THE EMBO JOURNAL, Vol. 21, Iss. 17, 2002-09 ,pp. : 4491-4499

John Wiley & Sons Inc

Access to resources Recommend Favorite

NKCC2 activity is inhibited by the Bartter's syndrome type 5 gain‐of‐function CaR‐A843E mutant in renal cells

By  

BIOLOGY OF THE CELL (ELECTRONIC), Vol. 107, Iss. 4, 2015-04 ,pp. : 98-110

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gain‐of‐function HCN2 variants in genetic epilepsy

By  

HUMAN MUTATION, Vol. 39, Iss. 2, 2018-02 ,pp. : 202-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform

By Tian Na   Li Jialiang   Shi Jinming   Sui Guangchao  

International Journal of Molecular Sciences, Vol. 18, Iss. 3, 2017-03 ,pp. : 191-191

MDPI

Access to resources Recommend Favorite